Advances in therapeutic treatment options for ANCA-associated vasculitis

被引：6

作者：

Carpenter, Shealynn ^{[1
]}

Cohen Tervaert, Jan Willem ^{[1
,2
]}

Yacyshyn, Elaine ^{[1
]}

机构：

[1] Univ Alberta, Dept Med, Div Rheumatol, Edmonton, AB, Canada

[2] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands

来源：

EXPERT OPINION ON ORPHAN DRUGS | 2020年 / 8卷 / 04期

关键词：

ANCA-associated vasculitis; drug therapy; remission induction; maintenance therapy; ANTIBODY-ASSOCIATED VASCULITIS; AZATHIOPRINE MAINTENANCE THERAPY; DAILY ORAL CYCLOPHOSPHAMIDE; TERM-FOLLOW-UP; REMISSION INDUCTION; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; EOSINOPHILIC GRANULOMATOSIS; MYCOPHENOLATE-MOFETIL; CLINICAL-OUTCOMES;

D O I：

10.1080/21678707.2020.1760837

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: ANCA-associated vasculitis (AAV) is a group of life-threatening autoimmune conditions that require a combination of treatments for induction and maintenance therapy. High-dose glucocorticoids and cyclophosphamide have traditionally been the mainstay of AAV treatment. During the last decade, rituximab has proven to be an effective alternative to cyclophosphamide. Currently, significant research in alternative therapeutic options for both induction and maintenance treatment is underway. Areas covered: Guideline review of remission, induction, and maintenance therapy of AAV. Examination of current research on alternative advanced therapeutics, specifically, the evidence for rituximab, C5a inhibitors, and trimethoprim-sulfamethoxazole. Expert opinion: Toxicities of existing therapies for AAV need to be limited, with alternative methods and agents for induction and maintenance. Importantly, the side-effects of high dose and long-term steroids have now been recognized. Newer induction agents and maintenance regimes will lead the future of AAV treatment.

引用

页码：127 / 136

页数：10

共 83 条

[1] Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis
Alberici, Federico
Smith, Rona M.
Jones, Rachel B.
Roberts, Darren M.
Willcocks, Lisa C.
Chaudhry, Afzal
Smith, Kenneth G. C.
Jayne, David R. W.
[J]. RHEUMATOLOGY, 2015, 54 (07) : 1153 - 1160
[2] Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre
Besada, Emilio
Koldingsnes, Wenche
Nossent, Johannes C.
[J]. RHEUMATOLOGY, 2013, 52 (11) : 2041 - 2047
[3] Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients
Calich, Ana Luisa
Puechal, Xavier
Pugnet, Gregory
London, Jonathan
Terrier, Benjamin
Charles, Pierre
Mouthon, Luc
Guillevin, Loic
[J]. JOURNAL OF AUTOIMMUNITY, 2014, 50 : 135 - 141
[4] Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's) Ten-year experience at a single center
Cartin-Ceba, Rodrigo
Golbin, Jason M.
Keogh, Karina A.
Peikert, Tobias
Sanchez-Menendez, Marta
Ytterberg, Steven R.
Fervenza, Fernando C.
Specks, Ulrich
[J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (11): : 3770 - 3778
[5] Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
Chanouzas, Dimitrios
McGregor, Julie Anne G.
Nightingale, Peter
Salama, Alan D.
Szpirt, Wladimir M.
Basu, Neil
Morgan, Matthew David
Poulton, Caroline J.
Draibe, Juliana Bordignon
Krarup, Elizabeth
Dospinescu, Paula
Dale, Jessica Anne
Pendergraft, William Franklin
Lee, Keegan
Egfjord, Martin
Hogan, Susan L.
Harper, Lorraine
[J]. BMC NEPHROLOGY, 2019, 20 (1)
[6] Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Charles, Pierre
Terrier, Benjamin
Perrodeau, Elodie
Cohen, Pascal
Faguer, Stanislas
Huart, Antoine
Hamidou, Mohamed
Agard, Christian
Bonnotte, Bernard
Samson, Maxime
Karras, Alexandre
Jourde-Chiche, Noemie
Lifermann, Francois
Gobert, Pierre
Hanrotel-Saliou, Catherine
Godmer, Pascal
Martin-Silva, Nicolas
Pugnet, Gregory
Matignon, Marie
Aumaitre, Olivier
Viallard, Jean-Francois
Maurier, Francois
Meaux-Ruault, Nadine
Riviere, Sophie
Sibilia, Jean
Puechal, Xavier
Ravaud, Philippe
Mouthon, Luc
Guillevin, Loic
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (08) : 1144 - 1150
[7] Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
Cortazar, Frank B.
Muhsin, Saif A.
Pendergraft, William F., III
Wallace, Zachary S.
Dunbar, Colleen
Laliberte, Karen
Niles, John L.
[J]. KIDNEY INTERNATIONAL REPORTS, 2018, 3 (02): : 394 - 402
[8] Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
de Groot, K
Rasmussen, N
Bacon, PA
Tervaert, JWC
Feighery, C
Gregorini, G
Gross, WL
Luqmani, R
Jayne, DRW
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (08): : 2461 - 2469
[9] Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
de Groot, Kirsten
Harper, Lorraine
Jayne, David R. W.
Suarez, Luis Felipe Flores
Gregorini, Gina
Gross, Wolfgang L.
Luqmani, Rashid
Pusey, Charles D.
Rasmussen, Niels
Sinico, Renato A.
Tesar, Vladimir
Vanhille, Philippe
Westman, Kerstin
Savage, Caroline O. S.
[J]. ANNALS OF INTERNAL MEDICINE, 2009, 150 (10) : 670 - U3
[10] Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data
de Joode, Anoek A. E.
Sanders, Jan Stephan F.
Puechal, Xavier
Guillevin, Loic P.
Hiemstra, Thomas F.
Flossmann, Oliver
Rasmussen, Nils
Westman, Kerstin
Jayne, David R.
Stegeman, Coen A.
[J]. RHEUMATOLOGY, 2017, 56 (11) : 1894 - 1901

← 1 2 3 4 5 6 7 8 9 →